Medicina
Departament
Pfizer (United States)
Nueva York, Estados UnidosPublicacions en col·laboració amb investigadors/es de Pfizer (United States) (31)
2022
-
Mapping genomic loci implicates genes and synaptic biology in schizophrenia
Nature, Vol. 604, Núm. 7906, pp. 502-508
2021
-
Management of particular clinical situations in psoriatic arthritis: an expert’s recommendation document based on systematic literature review and extended Delphi process
Rheumatology International, Vol. 41, Núm. 9, pp. 1549-1565
2020
-
Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 22, Núm. 1
-
The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review
Rheumatology and Therapy, Vol. 7, Núm. 2, pp. 237-257
2019
-
Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis
Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715
2018
-
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579
2017
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study
Arthritis Research and Therapy, Vol. 19, Núm. 1
2016
2015
-
Prevalence and clinical features of psoriatic arthritis in psoriasis patients in spain. Limitations of PASE as a screening tool
European Journal of Dermatology, Vol. 25, Núm. 1, pp. 57-63
2014
-
Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder
International Journal of Neuropsychopharmacology, Vol. 17, Núm. 5, pp. 685-695
-
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma
Journal of Clinical Oncology, Vol. 32, Núm. 8, pp. 760-767
2013
-
A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs
Annals of Clinical Psychiatry, Vol. 25, Núm. 1, pp. 17-26
2012
-
Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice
European Psychiatry, Vol. 27, Núm. 4, pp. 301-307
-
Quality of life in depressed women over 40 years old
Actas Espanolas de Psiquiatria, Vol. 40, Núm. 4, pp. 221-227
2011
-
Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: Is there still room for improvement?
Annals of General Psychiatry, Vol. 10
-
Effects of pregabalin on subjective sleep disturbance symptoms during withdrawal from long-term benzodiazepine use
European Addiction Research, Vol. 17, Núm. 5, pp. 262-270
-
High-dose etanercept in ankylosing spondylitis: Results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)
Rheumatology, Vol. 50, Núm. 10, pp. 1828-1837
-
Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study
European Neuropsychopharmacology, Vol. 21, Núm. 12, pp. 867-875
2010
-
Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort
Schizophrenia Research, Vol. 119, Núm. 1-3, pp. 101-109